Genetics in Drug Discovery
- 23 April 2021
- journal article
- editorial
- Published by Elsevier in Trends in Genetics
- Vol. 37 (7) , 603-605
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Evinacumab for Homozygous Familial HypercholesterolemiaNew England Journal of Medicine, 2020
- Evaluating drug targets through human loss-of-function genetic variationNature, 2020
- Insufficient Evidence for “Autism-Specific” GenesThe American Journal of Human Genetics, 2020
- Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approvalPLOS Genetics, 2019
- Inotersen Treatment for Patients with Hereditary Transthyretin AmyloidosisNew England Journal of Medicine, 2018
- Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin AmyloidosisNew England Journal of Medicine, 2018
- Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65 -mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trialThe Lancet, 2017
- Human knockouts and phenotypic analysis in a cohort with a high rate of consanguinityNature, 2017
- The support of human genetic evidence for approved drug indicationsNature Genetics, 2015
- Exome Sequencing,ANGPTL3Mutations, and Familial Combined HypolipidemiaNew England Journal of Medicine, 2010